Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.35 |
| ▸ | CA2 | P00918 | 9/20 | 0.35 |
| ▸ | CA12 | O43570 | 7/20 | 0.35 |
| ▸ | CA9 | Q16790 | 6/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19274714 | 1.00 | CA1 (0.35) | CA1CA2CA12CA9BRD9 | |
| SCHEMBL19274560 | 0.86 | KDM4A (0.35) | CA1CA2CA9KDM4ACA7 | |
| SCHEMBL19259981 | 0.86 | LOXL3 (0.36) | LOXL3LOXL2LOX | |
| SCHEMBL19274827 | 0.84 | KDM4A (0.34) | KDM4A | |
| SCHEMBL30699946 | 0.84 | ALDH1A1 (0.33) | MMP13 | |
| SCHEMBL29971317 | 0.81 | LOX (0.51) | LOXL3LOXL2LOX | |
| SCHEMBL19274454 | 0.81 | LOX (0.51) | LOXL3LOXL2LOX | |
| SCHEMBL19274513 | 0.78 | KDM4A (0.43) | CA1CA12KDM4AMMP13CA7 | |
| SCHEMBL29971392 | 0.77 | IDO1 (0.41) | CA1CA2CA12CA9KDM4A | |
| SCHEMBL28657087 | 0.76 | LOXL2 (0.36) | LOXL3LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | CA1 4769/4885CA2 3985/4885CA12 4411/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CA1 4769/4885CA2 3985/4885CA12 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.